Background

Vivek had been in pharmaceutical sales for eleven years. He was good at it — consistently in the top 20% of his regional team, twice awarded regional performer of the quarter, and promoted to Territory Sales Manager at 31, managing a team of seven medical sales representatives across the western Maharashtra territory for a mid-sized Indian pharma company.

From the outside, the picture looked solid. The salary was stable — ₹14.8 LPA plus incentives. The role had clear metrics: doctor relationships managed, prescriptions influenced, territory revenue growth. He knew the product portfolio by heart, understood formulary cycles, and had built a genuine network of physicians, hospital procurement officers, and distributor contacts across Pune and Nashik.

From the inside, something had gone flat. Vivek described it as a "grey feeling" — the sense that each month was a repetition of the last, that the sales cycles were interchangeable, and that the most intellectually demanding part of his job had slowly been automated or standardised. He felt capable of more. He didn't know what more looked like.

At 35, he was looking at his next ten years in pharma with a growing unease. Senior management roles in his company were few, filled slowly, and required either a pharmaceutical background at an MBA level he didn't have or a decade more of territorial climbing that he found deeply uninspiring. Lateral moves within pharma felt like rearranging furniture. But leaving — for what?

He arrived at Dheya after six months of researching career transitions online without finding anything that felt concrete enough to act on. He was not in crisis. He was, perhaps more damagingly, in stagnation.

The Challenge

The challenge Vivek faced is among the most common in career counselling for mid-career professionals: how to move out of a sector where you are competent but disengaged, when your entire visible credential set is sector-specific.

Pharma sales experience reads, to most hiring managers outside the industry, as pharma sales experience — and nothing else. The assumption is that the skills involved are product-specific, the relationship network is non-transferable, and the sales methodology is limited to a healthcare context. This assumption is largely incorrect, but it is pervasive, and it means that career-changers from pharma, like career-changers from defence and elite sport, face a translation problem as much as a capability problem.

The specific risk for someone like Vivek — mid-30s, manager level, eleven years' tenure — is that the window for a lateral move into a new industry narrows quickly. At 35, he could move as a senior contributor entering a new sector and reach director level by 40. At 40, the same move is harder to frame, slower to credential, and comes with higher opportunity cost.

The other challenge was compensation anchoring. Vivek had built a salary, an incentive structure, and a lifestyle around ₹14.8 LPA plus roughly ₹2–3 LPA in variable pay. A career move that required a salary reset — even temporarily — was genuinely difficult for his household. The financial dimension of the transition was real and needed to be planned for, not dismissed.

The Intervention

Vivek's RAPD assessment showed a high-Analytical (79th percentile), high-Directive (72nd) profile with moderate Relational (60th) and lower Practical (44th). This profile is strongly associated with roles that combine data-informed persuasion with confident autonomous decision-making — the core skill set of high-performance B2B sales in consultative selling environments.

Pharma sales at Vivek's level is fundamentally consultative: it requires understanding a complex client's workflow (the physician's prescribing behaviour), identifying where a product's evidence base addresses a genuine clinical problem, and building a relationship in which the product recommendation feels like a service rather than a transaction. This is not simple order-taking. It is a structured, evidence-based sales process with a high degree of autonomy and rigorous performance measurement.

These are precisely the skills that fintech B2B sales organisations value — and compete aggressively to acquire. The fintech B2B landscape in India — payment solutions, lending infrastructure, treasury management platforms, insurance distribution technology — is characterised by complex sales cycles, technical product portfolios, sophisticated client stakeholders (CFOs, CTOs, operations heads), and high-value accounts. The parallel with pharma — sophisticated buyer, complex product, evidence-based selling — is structural, not superficial.

The Skills Transfer Inventory quantified this overlap systematically. Across 24 core sales competencies, Vivek's pharma experience mapped at "high" or "very high" onto 19 of them in a fintech context. The five gaps were product-specific: financial product knowledge, regulatory familiarity with RBI frameworks, digital platform demonstration skills, and familiarity with fintech competitive landscape. These were genuine gaps — but they were learnable in 8–12 weeks of structured self-study.

Vivek's counsellor designed a targeted preparation plan: a 6-week self-study module covering fintech product categories (lending, payments, enterprise treasury), followed by informational conversations with five fintech sales professionals identified through LinkedIn — not job applications, just structured learning conversations. Each conversation was prepared with a set of specific questions and followed up with a thank-you note that advanced the relationship.

The resume was rebuilt with a specific reframe strategy. The word "pharmaceutical" appeared nowhere in the headline or summary. Instead: "B2B Sales Leader | Complex Sales Cycles | Evidence-Based Selling | ₹40Cr+ Territory Revenue Track Record." Each role description led with commercial outcomes (revenue managed, team performance metrics, account growth percentages) rather than product categories or therapeutic area names. The transferable language was everywhere. The sector-specific language was buried.

Job search targeting covered 31 fintech companies across Pune, Mumbai, and Hyderabad — specifically filtering for companies with B2B focus, enterprise or mid-market client base, and product lines requiring consultative sales (lending platforms, payment infra, compliance tech, and enterprise insurance distribution). Twenty-two applications were submitted over a five-week period, with each application accompanied by a one-paragraph cover note that explicitly drew the pharma-to-fintech analogy: "I've spent eleven years selling complex, evidence-based solutions to sophisticated, risk-averse buyers under competitive conditions. That's exactly what your enterprise sales team does — the product category has changed, the selling framework has not."

The Outcome

The conversion rate on applications was 32% to first-round interview — well above the typical 10–15% for career-change applications at the senior level. The explicit skills transfer narrative in cover notes was cited by three interviewers as the reason Vivek had made the shortlist despite not having fintech sector experience.

Vivek received two offers within 18 weeks of beginning the job search. He accepted a Senior Sales Manager role at a Mumbai-based lending infrastructure company serving mid-market businesses — specifically focused on MSME lending partnerships with NBFCs and private banks.

Starting CTC: ₹20.8 LPA fixed, plus performance variable that could take total compensation to ₹25–27 LPA — a 40% increase on his pharma base salary.

The hiring manager, a former FMCG sales director who had himself made a sector transition, told Vivek during the offer call: "We've been burned hiring people who knew fintech but couldn't sell. You clearly know how to sell — the product knowledge we can teach."

Six months into the role, Vivek had closed two accounts ahead of target, was shortlisted for an internal "New Joiners Excellence" recognition, and had been asked to participate in interviewing two additional sales candidates — a formal signal of trust from the leadership team.

"I spent six months being afraid that my eleven years didn't count outside pharma," he said. "The skills inventory showed me that eleven years of evidence-based B2B selling counts everywhere."

Lessons from This Case

Sector-specific language in resumes creates invisible walls for career-changers. Vivek's pharma experience was a genuine credential — but when wrapped in industry jargon, it was opaque to fintech hiring managers. Translating into universal commercial language — revenue, cycle complexity, buyer sophistication — removes the wall.

Skills transfer analysis should quantify overlap, not just assert it. Telling a candidate "your skills transfer" is reassuring but ineffective. A structured inventory that maps 24 specific competencies and identifies the five genuine gaps — and the 8-week plan to close them — transforms a vague reassurance into a credible action plan.

The explicit skills transfer narrative in applications is a differentiator, not a risk. Candidates from non-traditional backgrounds often try to hide their sector difference. The opposite strategy — leading with the analogy and explaining the structural parallel — created a 32% conversion rate for Vivek, double the sector average.

Compensation continuity planning reduces transition risk tolerance anxiety. Vivek's household financial constraints were real. Planning the transition to achieve parity or improvement (rather than accepting a temporary reset) was not a compromise — it was the correct strategy, made possible by targeting the right level and framing the experience correctly.